Genzyme, a Sanofi company, received approval from the FDA for its manufacturing plant in Framingham, MA, for the production of Fabrazyme (agalsidase beta). This follows the recent approval by the European Medicines Agency (EMA) last week, and allows Genzyme to begin the process of returning patients to full dosing (1 mg/kg) levels. “We are very pleased with the FDA approval of our Framingham plant as we continue our manufacturing recovery and path forward to serve the Fabry patient community,” ...